Ultragenyx Pharmaceutical RARE
NASDAQ RARE
$15.22 +0.47 (+3.19%)
At close: Oct 2, 2026 · 4:00 PM EDT

Ultragenyx Pharmaceutical (RARE) Gains from Sales and Divestitures (2018)

Updated

Ultragenyx Pharmaceutical's Gains from Sales and Divestitures came in at $170.32 million for FY2018.

Analysis

Ultragenyx Pharmaceutical (RARE) Gains from Sales and Divestitures (2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Ultragenyx Pharmaceutical 1.50 Bn -302.56 Mn 180.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2018 40.30 Mn
Jun 30, 2018 40.32 Mn
Mar 31, 2018 130.00 Mn
API Access

Ultragenyx Pharmaceutical Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=RARE&period=max&api_key=YOUR_API_KEY